ITRM Iterum Therapeutics plc NASDAQ Q4 2025 results 03 Apr 2026: Earnings drivers and outlook

ITRM stock closed at $0.03 on 03 Apr 2026 as Iterum Therapeutics plc (NASDAQ) published its Q4 2025 results, market closed. Investors face a tight liquidity and clinical-readout story: Iterum remains a clinical-stage biotech developing sulopenem and other anti-infectives. Volume spiked to 49,297,937 shares, well above the 50-day average of 15,822,292, signalling heavy trading interest ahead of an April earnings window and upcoming announcements.

ITRM stock Q4 earnings spotlight and timing

Iterum reported Q4 2025 results around the close on 03 Apr 2026, with markets closed for the session. The company remains loss-making with trailing EPS of -0.72 and a negative PE of -0.04. Read management commentary and the earnings call transcript for detail source.

The financial release frames near-term catalysts: Phase III updates for sulopenem and regulatory steps. With the next formal earnings window flagged in filings, traders must watch press releases and SEC filings for timing and guidance.

ITRM stock financials and valuation metrics

Iterum trades at a market cap of $1,598,747.00 with enterprise value near $24,331,747.00, reflecting material net debt and small equity base. Revenue per share is 0.01 while net income per share is -0.59, showing ongoing R&D-driven losses. Price-to-sales is 4.10 and price averages are $0.22 (50-day) and $0.53 (200-day), both well above the current close.

Shares outstanding total 53,291,578. Current ratio is 2.13, cash per share is 0.24, and free cash flow per share is -0.44, underlining tight cash dynamics for a clinical-stage biotech.

ITRM stock technicals and market action

Technical indicators show ITRM is oversold on momentum: RSI 25.56 and CCI -185.66. The intraday range was $0.03 to $0.05, and on heavy volume the relative volume hit 3.12, suggesting unusually active trading. On trend, the 50-day average of $0.22 sits above the price, a bearish signal until sustained closes above that level.

Volatility measures are high: ATR 0.03 and Bollinger Band middle at $0.15. Traders chasing short-term moves should budget for wide swings and thin bid-ask spreads common in low-price biotechnology stocks.

Meyka AI rates ITRM with a score out of 100 and forecast

Meyka AI rates ITRM with a score out of 100: 69.98 | Grade: B | Suggestion: HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. These grades are informational and not financial advice.

Meyka AI’s forecast model projects $0.40 for ITRM stock (yearly projection). Against the current close of $0.03, that implies an upside of 1,247.07%. Forecasts are model-based projections and not guarantees. Use the model alongside clinical and cash-runway checks.

Risks, catalysts and sector context for ITRM stock

Primary catalysts are clinical readouts for sulopenem and regulatory interactions; successful outcomes could re-rate the stock materially. Key risks include cash runway, development setbacks, and thin liquidity given a market cap under $2.00M. The biotech sector remains sensitive to clinical news and funding flows.

Sector peers and short interest can amplify moves. For context and daily news flow see the Q4 earnings coverage source.

ITRM stock trading strategy, price targets and scenarios

Given clinical binary risk and tight cash, size positions small and set clear stop rules. Short-term traders may look for mean-reversion toward the 50-day average at $0.22, while event-driven traders focus on readout windows.

Realistic price targets: conservative $0.10 (+233.33%), base $0.40 (+1,233.33%), bull $1.00 (+3,233.33%). These targets reflect scenario analysis tied to clinical success, licensing, or fundraising outcomes and are not guarantees.

Final Thoughts

Key takeaways for ITRM stock after the market close on 03 Apr 2026: Iterum closed at $0.03 on heavy volume of 49,297,937 shares and remains a high-risk clinical-stage biotech with trailing EPS -0.72 and a small market cap of $1,598,747.00. Short-term price action will track clinical updates, cash runway signals, and microcap liquidity. Meyka AI’s model projects $0.40 over the next year, implying a theoretical upside of 1,247.07% from the current close; this projection is model-driven and not a promise. For active investors we recommend position sizing limits, milestone-based re-evaluation, and close monitoring of successive regulatory and trial updates. Use the earnings call transcript and official filings for the most reliable detail and combine that with Meyka AI’s real-time signals on our AI-powered market analysis platform for timely alerts

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.